NEW YORK—GCI Group has promoted Bill Martin to executive vice president and global healthcare practice leader, responsible for advancing global practice strategy while continuing to drive growth among GCI’s key North America healthcare clients.
Martin will continue to serve as senior counsel across GCI’s client roster, which includes Merck, Genentech, Boehringer Ingelheim and Cephalon among others. He also will be instrumental in developing GCI’s healthcare public affairs, issues management and influencer relations offerings in 2008.
Since joining GCI in 2004, Martin has played an increasing role in practice leadership, developing new offerings and forging new client relationships. He formed GCI Healthcare’s biotechnology and specialty pharmaceuticals unit, one that now includes core clients such as Genentech, Cephalon, Teva Specialty Pharmaceuticals, Endo Pharmaceuticals, Mission Pharmacal, TM Biosciences and others. He also has strengthened the relationship with long-term client Boehringer Ingelheim, adding new assignments in its cardiovascular franchise.